GlassScriptPhysician profile
Vikas Vujjini
NPI 1275989907
$2,741.84
in general payments reported to CMS, 2019-2025
22 companies · $550 in 2025
The $550 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $398 · 2023: $970 · 2024: $825 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.46 |
| Education | $148.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $576.09 | 2022-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $368.42 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $221.55 | 2022-2024 | Lokelma, Farxiga |
| Mallinckrodt Hospital Products INC. | $195.75 | 2022-2024 | Acthar |
| Medtronic, INC. | $147.67 | 2023 | Ellipsys Vascular Access System |
| Baxter Healthcare | $142.43 | 2025 | Renal - Acute |
| Takeda Pharmaceuticals U.S.A., INC. | $115.43 | 2022-2024 | Gattex |
| Novartis Pharmaceuticals Corporation | $110.09 | 2023-2024 | |
| Outset Medical INC | $102.56 | 2024 | |
| Ardelyx, INC. | $100.07 | 2024 | Xphozah 30 Mg, Ibsrela |
| Fresenius USA Marketing, INC. | $96.77 | 2022-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $90.37 | 2022-2024 | |
| Glaxosmithkline, LLC. | $85.39 | 2022-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $85.36 | 2022-2024 | Lupkynis |
| Vantive US Healthcare LLC | $72.30 | 2025 | Renal - Acute |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $64.55 | 2023-2024 | Veltassa |
| Opko Pharmaceuticals, LLC | $58.30 | 2023 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $26.13 | 2024 | Jynarque |
| Horizon Therapeutics Plc | $25.20 | 2023 | Krystexxa |
| Lilly USA, LLC | $24.09 | 2023 | Jardiance |
| Alexion Pharmaceuticals, INC. | $18.56 | 2022 | |
| Ani Pharmaceuticals, INC. | $14.76 | 2023 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Vujjini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.